Beate Rautenberg

1.9k total citations
19 papers, 345 citations indexed

About

Beate Rautenberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Beate Rautenberg has authored 19 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Beate Rautenberg's work include Advanced Breast Cancer Therapies (10 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Research Studies (5 papers). Beate Rautenberg is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Research Studies (5 papers). Beate Rautenberg collaborates with scholars based in Germany, Switzerland and United States. Beate Rautenberg's co-authors include Annette Hasenburg, Walter Fiedler, Barbara Ritter, James B. Rottman, Dorothea Wessiepe, Matthias Friedrich, M. Wolf, Djordje Atanackovic, Maxim Kebenko and Sabine Stienen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Beate Rautenberg

16 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beate Rautenberg Germany	7	230	87	65	63	45	19	345
Anila Mehta United States	6	168 0.7×	133 1.5×	64 1.0×	83 1.3×	73 1.6×	9	392
Eriseld Krasniqi Italy	10	197 0.9×	59 0.7×	42 0.6×	93 1.5×	22 0.5×	21	342
Eszter Persa Hungary	9	165 0.7×	145 1.7×	173 2.7×	130 2.1×	29 0.6×	9	436
Oblaise Mercury United States	3	178 0.8×	99 1.1×	18 0.3×	63 1.0×	14 0.3×	5	325
Barbara O’Brien United States	14	180 0.8×	54 0.6×	46 0.7×	108 1.7×	12 0.3×	56	478
Xin Fan China	10	120 0.5×	102 1.2×	81 1.2×	134 2.1×	24 0.5×	28	463
Xiang Xu China	12	108 0.5×	46 0.5×	21 0.3×	121 1.9×	45 1.0×	35	320
Slavomir Krajnak Germany	12	194 0.8×	52 0.6×	40 0.6×	69 1.1×	17 0.4×	35	313
Élisabeth Daguenet France	11	126 0.5×	45 0.5×	52 0.8×	298 4.7×	26 0.6×	45	609
Debayan Mukherjee United Kingdom	11	80 0.3×	55 0.6×	137 2.1×	102 1.6×	32 0.7×	15	324

Countries citing papers authored by Beate Rautenberg

Since Specialization

Citations

This map shows the geographic impact of Beate Rautenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beate Rautenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beate Rautenberg more than expected).

Fields of papers citing papers by Beate Rautenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beate Rautenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beate Rautenberg. The network helps show where Beate Rautenberg may publish in the future.

Co-authorship network of co-authors of Beate Rautenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Beate Rautenberg. A scholar is included among the top collaborators of Beate Rautenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beate Rautenberg. Beate Rautenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Bjelic‐Radisic, Vesna, Maike Schmidt, Julia Rey, et al.. (2025). 310P Quality of life with first-line ET + palbociclib vs standard mono-chemotherapy in high risk HER2-/HR+ mBC and indication for chemotherapy in the PADMA study. ESMO Open. 10. 104882–104882.

Rautenberg, Beate, et al.. (2025). Development and Validation of Integrated Palliative Care Outcome Scale Short Form for Efficient Specialist Palliative Care Screening in Oncology (ScreeningPALL): A Cross-Sectional Study. Journal of Palliative Medicine. 28(4). 453–460.

Loibl, Sibylle, Marc Thill, Julia Rey, et al.. (2025). Abstract LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study. Clinical Cancer Research. 31(12_Supplement). LB1–3. 1 indexed citations

Brucker, Cosima, Anne Engel, Thomas Göhler, et al.. (2025). 338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial. ESMO Open. 10. 104910–104910.

Brucker, Cosima, Thomas Decker, PA Fasching, et al.. (2023). 441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study. Annals of Oncology. 34. S366–S367. 1 indexed citations

Decker, Thomas, Cosima Brucker, Peter A. Fasching, et al.. (2023). 409P Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)). Annals of Oncology. 34. S354–S355. 2 indexed citations

Fasching, Peter A., Cosima Brucker, Thomas Decker, et al.. (2023). Abstract P4-01-03: Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA. Cancer Research. 83(5_Supplement). P4–1. 2 indexed citations

Jackisch, Christian, Cosima Brucker, Thomas Decker, et al.. (2023). Abstract P4-01-01: RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC. Cancer Research. 83(5_Supplement). P4–1. 1 indexed citations

Marmé, Frederik, Cosima Brucker, Thomas Decker, et al.. (2023). 411P Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)). Annals of Oncology. 34. S355–S356. 1 indexed citations

10.

Lüftner, Diana, Cosima Brucker, Thomas Decker, et al.. (2022). Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.. Journal of Clinical Oncology. 40(16_suppl). 1065–1065. 1 indexed citations

11.

Rautenberg, Beate, et al.. (2020). Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study. BMC Cancer. 20(1). 578–578. 55 indexed citations

12.

Göritz, Anja S., et al.. (2020). How Distressed Are Cancer Patients when They Get Discharged from Hospital? Patients’ Distress and its Associations with Health Care Professionals’ Communication Skills and Perceived Stress. OPUS (Augsburg University). 1–7. 1 indexed citations

13.

Loibl, Sibylle, Michael Untch, Nicole Burchardi, et al.. (2018). Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. Journal of Clinical Oncology. 36(15_suppl). 104–104. 43 indexed citations

14.

Kebenko, Maxim, M. Wolf, Annette Hasenburg, et al.. (2018). A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. OncoImmunology. 7(8). e1450710–e1450710. 138 indexed citations

15.

Loibl, Sibylle, Michael Untch, Nicole Burchardi, et al.. (2017). A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. Journal of Clinical Oncology. 35(15_suppl). 3062–3062. 10 indexed citations

16.

Sehouli, Jalid, Oliver Tomé, Oumar Camara, et al.. (2016). A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). Journal of Cancer Research and Clinical Oncology. 143(3). 541–550. 14 indexed citations

17.

Rautenberg, Beate, et al.. (2016). Fallbericht einer Trastuzumab-Therapie während der Schwangerschaft bei metastasiertem Mammakarzinom. Zeitschrift für Geburtshilfe und Neonatologie. 220(2). 81–83. 4 indexed citations

18.

Farthmann, Juliane, Aida Hanjalic-Beck, J. Veit, et al.. (2016). The impact of chemotherapy for breast cancer on sexual function and health-related quality of life. Supportive Care in Cancer. 24(6). 2603–2609. 42 indexed citations

19.

Schmah, Oliver, J. W. Siebers, Stefan Zschiedrich, et al.. (2011). Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial). BMC Cancer. 11(1). 337–337. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact